ライフサイエンスコーパス: cell surface antigen

1 roteins, LAT2 and the heavy chain of the 4F2 cell surface antigen.

2 zation of a heretofore uncharacterized human cell surface antigen.

3 es than unconjugated mAbs targeting the same cell surface antigen.

4 eric antigen receptors (CARs) for a specific cell-surface antigen.

5 of radioimmunotherapy by targeting other NHL cell surface antigens.

6 election of panels of specific antibodies to cell surface antigens.

7 glycosylphosphatidylinositol (GPI)-anchored cell surface antigens.

8 n D in conjunction with the dual staining of cell surface antigens.

9 glycosylphosphatidylinositol (GPI)-anchored cell surface antigens.

10 dentify Fabs selectively reactive with tumor cell surface antigens.

11 xpression of c mu, myeloid, erythroid, and T-cell surface antigens.

12 f cells with concurrent immunophenotyping of cell surface antigens.

13 are restricted to targeting lineage-specific cell surface antigens.

14 ns and display a number of activation-linked cell surface antigens.

15 cal model of multivalent antibody binding to cell surface antigens.

16 d by loss of immune tolerance to nuclear and cell surface antigens.

17 nd nearby genes also encoding immunodominant cell surface antigens.

18 to trigger the expression of ICAM-1 and CD40 cell surface antigens.

19 ge, multi-copy gene families that encode red cell surface antigens.

20 changes in their morphology or expression of cell surface antigens.

21 hibited monoclonal antibody binding to key T-cell surface antigens.

22 of antibodies that bound to prostate cancer cell surface antigens.

23 patient or donor T cells to target specific cell-surface antigens.

24 s are primarily defined by the expression of cell-surface antigens.

25 GE-A3 pulsing on DC phenotypic expression of cell-surface antigens.

26 mouse ROR2 but not human ROR1 or other human cell-surface antigens.

27 ed cultures with >400 antibodies recognizing cell-surface antigens.

28 f fully human monoclonal antibodies to B-CLL cell-surface antigens.

29 ecan (SG), a first-in-class anti-trophoblast cell surface antigen 2 (Trop-2) antibody-drug conjugate,

30 folate receptor alpha (FRalpha), trophoblast cell surface antigen 2 (TROP-2), mesothelin (MSLN), sodi

31 dermal growth factor receptor 3, trophoblast cell surface antigen 2, c-MET, carcinoembryonic antigen-

32 ituzumab govitecan (SG), an anti-trophoblast cell-surface antigen 2 (anti-Trop-2) antibody-drug conju

33 verall survival and endpoints by trophoblast cell-surface antigen 2 (Trop-2) expression and other var

34 an antibody targeting the human trophoblast cell-surface antigen 2 (Trop-2), which is expressed in t

35 ntibody, which targets the human trophoblast cell-surface antigen 2 (Trop-2), with SN-38, which is co

36 Trophoblast cell-surface antigen 2 (TROP2) is overexpressed in advan

37 ), delta-like ligand 3 (DLL3), trophoblastic cell-surface antigen 2 (TROP2), prostate stem cell antig

38 Trophoblast cell-surface antigen 2 (TROP2)-directed antibody-drug co

39 ng HER3 (patritumab deruxtecan), trophoblast cell-surface antigen 2 [datopotamab deruxtecan and sacit

40 with an SN-38 payload targeting trophoblast cell-surface antigen 2, an epithelial antigen expressed

41 ng antibody-drug conjugates (eg, trophoblast cell-surface antigen 2, human epidermal growth factor re

42 t central review (BICR) with the trophoblast cell-surface antigen 2-directed antibody-drug conjugate

43 Sacituzumab govitecan (SG), a trophoblast cell surface antigen-2 (Trop-2)-directed antibody-drug c

44 Sacituzumab govitecan (SG) is a trophoblast cell surface antigen-2-directed antibody-drug conjugate

45 Using the MAb 2117, the cell surface antigen 2117 (Ag 2117) was cloned.

46 or the discovery of Fabs reactive with novel cell surface antigens a phage-expressed human antibody l

47 Upon encountering cell-surface antigens, actin-driven B-cell spreading amp

48 otpourri of complex target molecules such as cell surface antigens, allergens, and food contaminants.

49 a synthetic receptor that recognizes a tumor cell surface antigen and causes the T cell to kill the t

50 CD22 is a nearly universally expressed B-cell surface antigen and the efficacy of a CD22-directed

51 onoclonal antibodies targeting neuroblastoma cell surface antigens and attached cells were removed us

52 othelioma-associated, clinically represented cell surface antigens and further exploited the internal

53 d, in principle, serve as superior mimics of cell surface antigens and hence, as multifaceted cancer

54 t of targeted biologics that recognize tumor cell surface antigens and of specific inhibitors of path

55 d, in principle, serve as superior mimics of cell surface antigens and, hence, as potent cancer vacci

56 er inputs: the simultaneous expression of a (cell surface) antigen and secreted enzyme to generate fu

57 nfirms and extends reports of alterations in cell-surface antigens and drug sensitivity correlated wi

58 BsAb may target various cell-surface antigens and exist in different formats.

59 tibody to gamma-sarcoglycan, a cardiomyocyte cell surface antigen, and mixed with freshly isolated ne

60 rotein belonging to the Ly-6/Thy-1 family of cell surface antigens, and a murine homologue has been d

61 lyclonal, recognizing both intracellular and cell surface antigens, and HSP60 was identified as one c

62 y encoded intra- and extracellular proteins, cell surface antigens, and metabolically labeled glycoco

63 ies bound both yeast-displayed and mammalian cell surface antigens, and were endocytosed upon binding

64 s of neurons express distinct complements of cell-surface antigens, and that the regulation of CSPG e

65 By targeting internalizing cell surface antigens, antibody-siRNA complexes provide

66 l activity following binding to glycosylated cell-surface antigens, are emerging as attractive target

67 f eight was initially selected from 95 human cell surface antigens as each was shared among human ova

68 as measured by expression of CD11b and CD66b cell surface antigens, as well as reduction of nitroblue

69 1 of HSPG2 (perlecan) protein as the cognate cell surface antigen bound by the antibody.

70 lobulin G and M antibodies against different cell surface antigens, but not to antibody-dependent cel

71 using a two-step approach: i) recognition of cell surface antigen by a morpholino oligonucleotide-mod

72 vidual backcross mice were also examined for cell surface antigen by fluorescence-activated cell sort

73 neth cells respond to bacteria and bacterial cell surface antigens by discharging secretory granules

74 bodies that recognized senescence-associated cell-surface antigens by FACS analysis and a newly devel

75 Initially, the loss of a cell-surface antigen can occur due to drift in isolated

76 eisserial lipooligosaccharide (LOS), a major cell-surface antigen, can be correlated with inflammator

77 Expression of the cell-surface antigen CD10 has long been used to define t

78 In this study, we found that the cell surface antigen CD13, a multifunctional transmembra

79 methylation pattern for one such marker, the cell surface antigen CD133 (Prominin 1).

80 de (LPS), LPS-binding protein (LBP), and the cell surface antigen CD14.

81 y of adoptive T cell therapies targeting the cell surface antigen CD19 has been demonstrated in hemat

82 b, a monoclonal antibody which targets the B cell surface antigen CD20 and results in a rapid and sus

83 In resting cells the B-cell surface antigen CD20 is associated with the BCR but

84 herapeutic monoclonal antibodies against the cell surface antigen, CD20, has revolutionized the treat

85 itive and specific detection of a variety of cell surface antigens (CD3, CD20, and epithelial membran

86 The cell surface antigens CD33 and CD45 are attractive targe

87 ed hematopoietic precursor cells express the cell surface antigen CD34 and the hematopoietic transcri

88 maker markers including MYH11, BMP4, and the cell surface antigen CD34.

89 e studied, we analyzed the expression of the cell surface antigens CD34, CD71 and CD235a, which are m

90 uced maturation protein-1 (BLIMP-1), and the cell surface antigens CD38 and CD138/Syndecan-1.

91 is mainly mediated through ligation of the B-cell surface antigen, CD40, by its cognate T-cell ligand

92 The cell surface antigen CD44v6 is a potential pan-cancer ta

93 Immunohistochemistry was performed for cell surface antigens (CD68 for macrophages, CD4 for lym

94 lls coexpression vectors containing cDNAs of cell surface antigen CD7 and either RAR alpha, RAR beta,

95 In this study, we identified the cell surface antigen CD99 as notably expressed in DMGs,

96 d that has grown to include soluble markers, cell-surface antigens, cell-cycle-related proteins, and

97 rologic syndromes and the discovery of novel cell surface antigen central nervous system autoimmune s

98 c differentiation, with both morphologic and cell-surface antigen changes, as well as resistance both

99 Thus, ALPPL2 belongs to a rare class of cell surface antigens classified as truly tumor specific

100 eta2m in peptide-based vaccines may increase cell surface antigen densities above thresholds that all

101 Cell surface antigen discovery is of great interest for

102 We analyzed the expression of various cell surface antigens during a 30-day period after the d

103 protein (PfGARP) is a recently characterized cell surface antigen encoded by Plasmodium falciparum, t

104 e, including one that disrupted the putative cell surface antigen encoding gene, sca1 considered to b

105 tion against a cocktail containing bacterial cell-surface antigens enhanced disease severity as teste

106 lyl Cyclase C (GUCY2C) is a tumor-associated cell surface antigen expressed across gastrointestinal m

107 l tumors show that the antibody recognizes a cell surface antigen expressed by the majority of colore

108 brane antigen (PSMA) is a well-characterized cell surface antigen expressed by virtually all prostate

109 opulations, is frequently accomplished using cell surface antigens expressed by the cells of interest

110 ion of immunoglobulin G antibodies targeting cell surface antigens expressed in multiple cGVHD affect

111 lls label free using the specific binding of cell surface antigens expressed on the surface of cancer

112 Prostate stem-cell antigen (PSCA) is a cell-surface antigen expressed in normal prostate and ov

113 produce monoclonal antibodies that recognize cell-surface antigens expressed by hematopoietic precurs

114 and immunocytochemical characterization of a cell surface antigen, expressed on globose basal cells (

115 bacterial probiotic cocktail VSL#3 to alter cell surface antigen expression and cytokine production

116 stem cells into clinical applications, their cell surface antigen expression and its chemical structu

117 edly inhibited IL-4-mediated mitogenesis and cell surface antigen expression and was not tyrosine pho

118 We used flow cytometry to characterize cell surface antigen expression on human testicular cell

119 EPCs are generally identified by cell surface antigen expression or counting in a commerc

120 Bronchoalveolar cell profiles, cell surface antigen expression, and superoxide anion pr

121 nd purified subpopulations were assessed for cell surface antigen expression, morphology, and functio

122 c probes for PET that are based on targeting cell surface antigen expression.

123 d by magnetic bead selection on the basis of cell surface antigen expression.

124 t contamination by exploiting differences in cell surface antigen expression.

125 Identification of cell-surface antigen expression associated with hematopo

126 y and on completion of treatment, lymphocyte cell-surface antigen expression was determined by flow c

127 Cell-surface antigen expression was restricted to primar

128 lial antigen of the prostate 1 (STEAP1) is a cell surface antigen for therapeutic targeting in prosta

129 l to target essentially any tumor-associated cell-surface antigen for which a monoclonal antibody can

130 CD34(++)CD45(low) cells express many cell surface antigens found on multipotent primitive hem

131 In addition, this B-cell surface antigen has been shown recently to be an ef

132 Identification of tumor-specific cell surface antigens has proven challenging, as the vas

133 In recent years, novel specific cell surface antigens have allowed identification of leu

134 arious mature blood lineages, a diversity of cell surface antigens have also been specifically recogn

135 Radiolabeled antibodies directed against B-cell surface antigens have emerged as effective and safe

136 cancer, monoclonal antibodies (mAbs) against cell surface antigens have not lived up to their initial

137 tment of Gaucher disease, and a small murine cell surface antigen (heat-stable antigen [HSA]) as a se

138 iral surface: one directed against the human cell surface antigen Her2neu, which belongs to the epide

139 n with monoclonal antibodies that react with cell-surface antigens, however, the protein A-envelope c

140 veloped for characterizing the expression of cell surface antigens, identifies RMEC as a population s

141 45 isoforms is that they interact with other cell surface antigens important in TCR signaling, alteri

142 other cancers, as a specifically upregulated cell surface antigen in high-risk myeloma tumors.

143 her polymorphic genes that result in altered cell surface antigens in cancers.

144 ly and therapeutically important soluble and cell-surface antigens in a single step from correspondin

145 of lymphopoiesis-related genes and lymphoid cell-surface antigens in LEF1high patients.

146 ntra-exonic recombination in a key family of cell-surface antigens in P. falciparum and thus likely f

147 Cell surface antigens, in addition to HLA, may serve as

148 antibodies (mainly IgG1) against a neuronal cell-surface antigen; in three patients antibodies were

149 pecific antibodies of different valencies to cell surface antigens including MET and EGF receptor, we

150 a suggest that vaccination against bacterial cell-surface antigens increases disease severity, but va

151 e-emitting radionuclides to tumor-associated cell surface antigens, inducing difficult-to-repair DNA

152 ferentiation, such as expression of specific cell surface antigens, inhibition of cell proliferation,

153 self-antigens, we sequestered a tolerogenic cell surface antigen intracellularly by addition of a tw

154 The CD34 cell surface antigen is a glycoprotein expressed by hema

155 The CD20 cell surface antigen is expressed at high levels by over

156 One such cell surface antigen is the ganglioside GD2.

157 The identification of tumor-specific cell surface antigens is a critical step toward the deve

158 The identification of cell surface antigens is critical to the development of

159 The identification of cell surface antigens is critical to the development of

160 conventional targeting against up-regulated cell surface antigens is limited by heterogeneity in exp

161 CA), a homologue of the Ly-6/Thy-1 family of cell surface antigens, is expressed by a majority of hum

162 rse additional modifications (e.g., terminal cell-surface antigens); it therefore plays important rol

163 which is manifested by the expression of the cell surface antigen known as epithelial cell adhesion m

164 The emergence of antibodies targeting tumor cell-surface antigens led to advancements in the treatme

165 A 62-kDa cell surface antigen (M9) of Mycoplasma gallisepticum PG

166 agen type IV), suggesting that the parasitic cell surface antigen may function as an adhesin.

167 Antibody binding to these cell surface antigens may lead to valve damage in rheuma

168 eir living donors and estimated all possible cell surface antigens mismatches for a given donor/recip

169 eagent can directly be used for detection of cell surface antigens obviating the laborious steps of p

170 HIT receptors are well suited for targeting cell surface antigens of low abundance.

171 ed rat monoclonal antibodies (MoAbs) against cell surface antigens of the mouse endothelioma cell lin

172 Using F(ab')2 fragments against a unique cell surface antigen on ACT cells (Thy1.1) or an enginee

173 0-month-old NZB splenocytes recognized pre-B cell surface antigens on both pre-B cell lines and on IL

174 ept, we generated DVD-ARCs targeting various cell surface antigens on multiple myeloma cells for the

175 onoclonal antibodies (mAbs) directed against cell-surface antigens on human hematopoietic cells combi

176 it is unknown whether autoantibodies against cell-surface antigens on human RPCs exist in DR patients

177 is caused by autoantibodies directed against cell-surface antigens on keratinocytes, which when targe

178 ocused on widely conserved, highly expressed cell-surface antigens, opening the door to new therapeut

179 e cells without purification on the basis of cell-surface antigens or anatomic location.

180 MN is a novel cell surface antigen originally detected in human HeLa c

181 ediators of tumor-driven angiogenesis, and B cell surface antigens other than CD20.

182 Prostate-specific membrane antigen (PSMA), a cell surface antigen overexpressed in PC, provides a val

183 uestration molecules, and the major secreted cell surface antigen p57 (also known as major soluble an

184 ck flagella (flaA, flaB, and flbA) or common cell surface antigen (peb1A) were constructed in strain

185 olic bioavailability in DCs without altering cell-surface antigens, potentially making it a more pote

186 CD5 and CD6, two type I cell surface antigens predominantly expressed by T cells

187 an AML stem cells involves first identifying cell surface antigens preferentially expressed on AML LS

188 clonal antibody (MoAb) that binds to a novel cell surface antigen present on a CD34(bright) subset of

189 The identification of novel cell surface antigens present on tumor cells is crucial

190 howed that these inhibitors induce increased cell-surface antigen presentation of transfected and end

191 f cells characterized by CD44(+)/CD24(-/low) cell-surface antigen profile that have high tumor-initia

192 re, we report single-cell transcriptomes and cell surface antigen profiles of over 24,000 cells from

193 From this, we identified and validated three cell surface antigens: PTPRG, ICAM1, and CADM1.

194 eptor zeta chain, and upon ligation of their cell-surface antigen receptor overproduce tyrosine phosp

195 IceMG cleaves B cell surface antigen receptors and inactivates phospholi

196 in vivo to adjust the signaling threshold of cell surface antigen receptors.

197 ial molecular link between the triggering of cell-surface antigen receptors and nuclear factor kappaB

198 T cells are activated by interaction of cell-surface antigen receptors with major histocompatibi

199 cate that AC133-2, not AC133-1, has been the cell surface antigen recognized by anti-AC133 monoclonal

200 al protein C receptor (EPCR) as a pathogenic cell surface antigen recognized by aPLs for induction of

201 nitor cells (OPCs) that are positive for the cell surface antigen recognized by the O4 antibody (O4(+

202 sing with CPD-MAGE-A3 did not alter specific cell-surface antigens required for T-cell activation.

203 O-Glycosylation of CD43, a cell surface antigen rich in O-glycans, was drastically

204 previously described hematopoietic or other cell surface antigen(s).

205 e family (mip-1beta and a tca3 homologue), a cell surface antigen sca-2 and the transcription factor

206 Here we report that the cell surface antigen sca4 of Rickettsia co-localizes wit

207 cines against GD2 (and possibly other cancer cell surface antigens) should be used exclusively in the

208 re differentiation digests an immunodominant cell surface antigen (SOWgp) and prevents host recogniti

209 ified an mAb that is capable of binding to a cell surface antigen specifically expressed on both andr

210 eted in 30 min, and extra time is needed for cell surface antigen staining.

211 Immunotherapy approaches targeting cell surface antigens such as CD-56 (BB10901) and GD3 ga

212 an be distinguished from LSCs by an array of cell surface antigens such as CD123, thus a candidate to

213 t, to the high cancer-specific expression of cell surface antigens such as mesothelin, which is overe

214 creening of antibody libraries against other cell surface antigens, such as transmembrane receptors,

215 Immunotherapies directed against cancer cell-surface antigens, such as chimeric antigen receptor

216 ies but had no effect on antibodies to other cell surface antigens, suggesting that GIF specifically

217 d by malignant plasma cells that express the cell surface antigen syndecan-1 (CD138); however, CD138

218 These approaches aim at myeloma cell surface antigens, T-cell immunity, and biological m

219 ndogenous T cell receptor) that combines (1) cell surface antigen targeting, (2) small-molecule regul

220 lioma, we identified a highly specific tumor cell surface antigen that can be targeted for therapy de

221 All patients had antibodies against neuronal cell surface antigens that by immunoprecipitation were f

222 Activation induces changes in T-cell surface antigens that may distinguish previously st

223 reater attention was given to genes encoding cell surface antigens that were selectively up-regulated

224 number provides the functional diversity of cell surface antigens that, in fungi and other pathogens

225 hymus to reconstitute T cells expressing CD4 cell-surface antigens that are lost during HIV infection

226 lity complex (MHC)-presentation-independent, cell-surface antigens that could be targeted by antibodi

227 antibodies, each corresponding to a specific cell-surface antigen, that have been functionalized in a

228 Once bound to the target cell-surface antigen, the conjugate must be processed to

229 e a Gram-negative cell envelope and a unique cell surface antigen; therefore, this approach should be

230 HSCT serum antibodies and subsequently B-CLL cell-surface antigens they recognize, we generated a hum

231 ection through vaccination against bacterial cell-surface antigens; thus far all have failed.

232 s is in accord with the presence of a common cell-surface antigen (TLA antigen) and similarities in t

233 r microarray can be used to screen red blood cell surface antigens using whole blood in a label-free

234 s, transcribes gene units encoding the major cell surface antigens variant surface glycoprotein and p

235 ve this by removing the glycan moieties from cell surface antigens via enzymatic digestion, a process

236 se) increases in cells, the stability of the cell surface antigen VlsE, which presumably did not evol

237 g of antibody fragments (Fabs) reactive with cell surface antigens was established and used to identi

238 ith brain immunohistochemistry optimized for cell-surface antigens was performed.

239 [PfRh2], MSP-119, and the infected red blood cell surface antigens were not.

240 oclonal antibodies raised against epithelial cell-surface antigens were screened for antigen expressi

241 es and cell-based assays with known neuronal cell-surface antigens were used.

242 In contrast to cell surface antigen, which causes the deletion of autor

243 ings identify ALPP2 as a true tumor-specific cell surface antigen whose tissue specificity enables th

244 uman cell lines efficiently by targeting the cell surface antigens with antibody-coated beads.

245 To identity novel mesothelioma cell surface antigens with broad subtype coverage and hi

246 Cell surface antigens with highly restricted expression

247 on monoclonal antibodies (mAbs) that target cell surface antigens with restricted expression in pedi

248 ll therapy is limited by the availability of cell surface antigens with sufficient cancer-specific ex

249 the tropism of adenovirus vectors to unique cell surface antigens would be an important development

250 bias, together with polyvalent attachment to cell surface antigen, would ensure that the IgM pentamer